Cite
HARVARD Citation
Terlizzi, M. et al. (2021). Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Acta oncologica. pp. 1114-1121. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Terlizzi, M. et al. (2021). Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Acta oncologica. pp. 1114-1121. [Online].